Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival
Authors:
Open Access
- 1 July 2014
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 20 (7) , 960-968
Abstract
No abstract availableKeywords
Funding Information
- Public Health Service Grant/Cooperative Agreement (U24-CA76518)
- National Cancer Institute (NCI)
- National Heart, Lung and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases
This publication has 37 references indexed in Scilit:
- Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic MalignanciesJAMA, 2011
- Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus CriteriaBlood, 2011
- Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignanciesBlood, 2011
- Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic SyndromeJournal of Clinical Oncology, 2010
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term OutcomesTransplantation and Cellular Therapy, 2009
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2009
- Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict SurvivalTransplantation and Cellular Therapy, 2008
- Similar and Promising Outcomes in Lymphoma Patients Treated with Myeloablative or Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2008
- Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative ConditioningTransplantation and Cellular Therapy, 2008